Advanced search
Publication Cover
Critical Reviews in Biochemistry and Molecular Biology Volume 48, 2013 - Issue 3
Submit an article Journal homepage
7,916
Views
536
CrossRef citations to date
0
Altmetric
Review Article

Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): The next decade

Jennifer VandoorenLaboratory of Immunobiology, Rega Institute for Medical Research, University of Leuven KU LeuvenBelgium
,
Philippe E. Van den SteenLaboratory of Immunobiology, Rega Institute for Medical Research, University of Leuven KU LeuvenBelgium
&
Ghislain OpdenakkerLaboratory of Immunobiology, Rega Institute for Medical Research, University of Leuven KU LeuvenBelgiumCorrespondence[email protected]
Pages 222-272 | Received 07 Dec 2012, Accepted 24 Jan 2013, Published online: 02 Apr 2013

References

  • Abu El-Asrar AM, Veckeneer N, Geboes K, et al. (1998). Gelatinase B in proliferative vitreoretinal disorders. Am J Ophthalmol 125:844–51
  • Abu El-Asrar AM, Geboes K, Al-Kharashi SA, et al. (2000). Expression of gelatinase B in trachomatous conjunctivitis. Br J Ophthalmol 84:85–91
  • Abu El-Asrar AM, Van Aelst I, Al-Mansouri S, et al. (2001). Gelatinase B in vernal keratoconjunctivitis. Arch Ophthalmol 119:1505–11
  • Adair JC, Charlie J, Dencoff JE, et al. (2004). Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease. Stroke 35:e159–62
  • Adhikary S, Kocieda VP, Yen JH, et al. (2012). Signaling through cannabinoid receptor 2 suppresses murine dendritic cell migration by inhibiting matrix metalloproteinase 9 expression. Blood 120:3741–9
  • Agrawal S, Anderson P, Durbeej M, et al. (2006). Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J Exp Med 203:1007–19
  • Agrawal SM, Lau L, Yong VW. (2008). MMPs in the central nervous system: where the good guys go bad. Semin Cell Dev Biol 19:42–51
  • Ahn GO, Brown JM. (2008). Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 13:193–205
  • Alexander CM, Hansell EJ, Behrendtsen O, et al. (1996). Expression and function of matrix metalloproteinases and their inhibitors at the maternal-embryonic boundary during mouse embryo implantation. Development 122:1723–36
  • Allavena P, Sica A, Garlanda C, Mantovani A. (2008). The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev 222:155–61
  • Anelli T, Mannello F, Salani M, et al. (2007). Acetylcholine induces neurite outgrowth and modulates matrix metalloproteinase 2 and 9. Biochem Biophys Res Commun 362:269–74
  • Aoudjit F, Esteve PO, Desrosiers M, et al. (1997). Gelatinase B (MMP-9) production and expression by stromal cells in the normal and adult thymus and experimental thymic lymphoma. Int J Cancer 71:71–8
  • Apte SS. (2009). A disintegrin-like and metalloprotease (reprolysin-type) with thrombospondin type 1 motif (ADAMTS) superfamily: functions and mechanisms. J Biol Chem 284:31493–7
  • Ardi VC, Kupriyanova TA, Deryugina EI, Quigley JP. (2007). Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci USA 104:20262–7
  • Ardi VC, Van den Steen PE, Opdenakker G, et al. (2009). Neutrophil MMP-9 proenzyme, unencumbered by TIMP-1, undergoes efficient activation in vivo and catalytically induces angiogenesis via a basic fibroblast growth factor (FGF-2)/FGFR-2 pathway. J Biol Chem 284:25854–66
  • Astarci E, Erson-Bensan AE, Banerjee S. (2012). Matrix metalloprotease 16 expression is downregulated by microRNA-146a in spontaneously differentiating Caco-2 cells. Dev Growth Differ 54:216–26
  • Atkinson JJ, Lutey BA, Suzuki Y, et al. (2011). The role of matrix metalloproteinase-9 in cigarette smoke-induced emphysema. Am J Respir Crit Care Med 183:876–84
  • Baker AH, Edwards DR, Murphy G. (2002). Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 115:3719–27
  • Balasubramanian S, Fan M, Messmer-Blust AF, et al. (2011). The interferon-gamma-induced GTPase, mGBP-2, inhibits tumor necrosis factor alpha (TNF-alpha) induction of matrix metalloproteinase-9 (MMP-9) by inhibiting NF-kappaB and Rac protein. J Biol Chem 286:20054–64
  • Bannikov GA, Karelina TV, Collier IE, et al. (2002). Substrate binding of gelatinase B induces its enzymatic activity in the presence of intact propeptide. J Biol Chem 277:16022–7
  • Barkho BZ, Munoz AE, Li X, et al. (2008). Endogenous matrix metalloproteinase (MMP)-3 and MMP-9 promote the differentiation and migration of adult neural progenitor cells in response to chemokines. Stem Cells 26:3139–49
  • Barrett AJ, Rawlings ND, Woessner JF. (2012). Handbook of proteolytic enzymes. London: Elsevier Academic Press
  • Bartholomé EJ, Van Aelst I, Koyen E, et al. (2001). Human monocyte-derived dendritic cells produce bioactive gelatinase B: inhibition by IFN-beta. J Interferon Cytokine Res 21:495–501
  • Bausch D, Pausch T, Krauss T, et al. (2011). Neutrophil granulocyte derived MMP-9 is a VEGF independent functional component of the angiogenic switch in pancreatic ductal adenocarcinoma. Angiogenesis 14:235–43
  • Bauvois B, Dumont J, Mathiot C, Kolb JP. (2002). Production of matrix metalloproteinase-9 in early stage B-CLL: suppression by interferons. Leukemia 16:791–8
  • Bekes EM, Schweighofer B, Kupriyanova TA, et al. (2011). Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation. Am J Pathol 179:1455–70
  • Bellini T, Trentini A, Manfrinato MC, et al. (2012). Matrix metalloproteinase-9 activity detected in body fluids is the result of two different enzyme forms. J Biochem 151:493–99
  • Bendrik C, Robertson J, Gauldie J, Dabrosin C. (2008). Gene transfer of matrix metalloproteinase-9 induces tumor regression of breast cancer in vivo. Cancer Res 68:3405–3412
  • Bergers G, Brekken R, McMahon G, et al. (2000). Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2:737–44
  • Bergin PJ, Raghavan S, Svensson H, et al. (2008). Gastric gelatinase B/matrix metalloproteinase-9 is rapidly increased in Helicobacter felis-induced gastritis. FEMS Immunol Med Microbiol 52:88–98
  • Berton A, Rigot V, Huet E, et al. (2001). Involvement of fibronectin type II repeats in the efficient inhibition of gelatinases A and B by long-chain unsaturated fatty acids. J Biol Chem 276:20458–65
  • Betsuyaku T, Shipley JM, Liu Z, et al. (1999). Neutrophil emigration in the lungs, peritoneum, and skin does not require gelatinase B. Am J Respir Cell Mol Biol 20:1303–9
  • Bhatt LK, Veeranjaneyulu A. (2010). Minocycline with aspirin: a therapeutic approach in the treatment of diabetic neuropathy. Neurol Sci 31:705–16
  • Biswas C, Zhang Y, DeCastro R, et al. (1995). The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 55:434–9
  • Biswas MH, Du C, Zhang C, et al. (2010). Protein kinase D1 inhibits cell proliferation through matrix metalloproteinase-2 and matrix metalloproteinase-9 secretion in prostate cancer. Cancer Res 70:2095–104
  • Bjorklund M, Heikkila P, Koivunen E. (2004). Peptide inhibition of catalytic and noncatalytic activities of matrix metalloproteinase-9 blocks tumor cell migration and invasion. J Biol Chem 279:29589–97
  • Blavier L, Delaisse JM. (1995). Matrix metalloproteinases are obligatory for the migration of preosteoclasts to the developing marrow cavity of primitive long bones. J Cell Sci 108:3649–59
  • Bolignano D, Donato V, Lacquaniti A, et al. (2010). Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: a new protein enters the scene. Cancer Lett 288:10–16
  • Bonacci G, Schopfer FJ, Batthyany CI, et al. (2011). Electrophilic Fatty acids regulate matrix metalloproteinase activity and expression. J Biol Chem 286:16074–81
  • Bongers G, de Esch I, Leurs R. (2010). Molecular pharmacology of the four histamine receptors. Adv Exp Med Biol 709:11–19
  • Borregaard N. (2010). Neutrophils, from marrow to microbes. Immunity 33:657–70
  • Bouchard F, Belanger SD, Biron-Pain K, St-Pierre Y. (2010). EGR-1 activation by EGF inhibits MMP-9 expression and lymphoma growth. Blood 116:759–66
  • Brzezinska AA, Johnson JL, Munafo DB, et al. (2008). The Rab27a effectors JFC1/Slp1 and Munc13–4 regulate exocytosis of neutrophil granules. Traffic 9:2151–64
  • Burg-Roderfeld M, Roderfeld M, Wagner S, et al. (2007). MMP-9-hemopexin domain hampers adhesion and migration of colorectal cancer cells. Int J Oncol 30:985–92
  • Butler GS, Apte SS, Willenbrock F, Murphy G. (1999). Human tissue inhibitor of metalloproteinases 3 interacts with both the N- and C-terminal domains of gelatinases A and B. Regulation by polyanions. J Biol Chem 274:10846–51
  • Byun HJ, Hong IK, Kim E, et al. (2006). A splice variant of CD99 increases motility and MMP-9 expression of human breast cancer cells through the AKT-, ERK-, and JNK-dependent AP-1 activation signaling pathways. J Biol Chem 281:34833–47
  • Calander AM, Starckx S, Opdenakker G, et al. (2006). Matrix metalloproteinase-9 (gelatinase B) deficiency leads to increased severity of Staphylococcus aureus-triggered septic arthritis. Microbes Infect 8:1434–9
  • Camp TM, Tyagi SC, Senior RM, et al. (2003). Gelatinase B(MMP-9) an apoptotic factor in diabetic transgenic mice. Diabetologia 46:1438–45
  • Campbell LG, Ramachandran S, Liu W, et al. (2005). Different roles for matrix metalloproteinase-2 and matrix metalloproteinase-9 in the pathogenesis of cardiac allograft rejection. Am J Transplant 5:517–28
  • Caron A, Desrosiers RR, Beliveau R. (2005). Ischemia injury alters endothelial cell properties of kidney cortex: stimulation of MMP-9. Exp Cell Res 310:105–16
  • Carstanjen D, Ulbricht N, Iacone A, et al. (2002). Matrix metalloproteinase-9 (gelatinase B) is elevated during mobilization of peripheral blood progenitor cells by G-CSF. Transfusion 42:588–96
  • Cauwe B, Martens E, Proost P, Opdenakker G. (2009). Multidimensional degradomics identifies systemic autoantigens and intracellular matrix proteins as novel gelatinase B/MMP-9 substrates. Integr Biol (Camb) 1:404–26
  • Cauwe B, Martens E, Sagaert X, et al. (2011). Deficiency of gelatinase B/MMP-9 aggravates lpr-induced lymphoproliferation and lupus-like systemic autoimmune disease. J Autoimmun 36:239–52
  • Cauwe B, Martens E, Van den Steen PE, et al. (2008). Adenylyl cyclase-associated protein-1/CAP1 as a biological target substrate of gelatinase B/MMP-9. Exp Cell Res 314:2739–49
  • Cauwe B, Opdenakker G. (2010). Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases. Crit Rev Biochem Mol Biol 45:351–423
  • Cauwe B, Van den Steen PE, Opdenakker G. (2007). The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit Rev Biochem Mol Biol 42:113–85
  • Cha H, Kopetzki E, Huber R, et al. (2002). Structural basis of the adaptive molecular recognition by MMP9. J Mol Biol 320:1065–79
  • Chakraborti S, Mandal M, Das S, et al. (2003). Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 253:269–85
  • Chattopadhyay S, Shubayev VI. (2009). MMP-9 controls Schwann cell proliferation and phenotypic remodeling via IGF-1 and ErbB receptor-mediated activation of MEK/ERK pathway. Glia 57:1316–25
  • Chen CY, Shyu AB. (1995). AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem Sci 20:465–70
  • Chen KC, Wang YS, Hu CY, et al. (2011). OxLDL up-regulates microRNA-29b, leading to epigenetic modifications of MMP-2/MMP-9 genes: a novel mechanism for cardiovascular diseases. FASEB J 25:1718–28
  • Cheng G, Wei L, Xiurong W, et al. (2009). IL-17 stimulates migration of carotid artery vascular smooth muscle cells in an MMP-9 dependent manner via p38 MAPK and ERK1/2-dependent NF-kappaB and AP-1 activation. Cell Mol Neurobiol 29:1161–8
  • Cheng JC, Chou CH, Kuo ML, Hsieh CY. (2006). Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway. Oncogene 25:7009–18
  • Cheung LW, Leung PC, Wong AS. (2006). Gonadotropin-releasing hormone promotes ovarian cancer cell invasiveness through c-Jun NH2-terminal kinase-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9. Cancer Res 66:10902–10
  • Chicheportiche Y, Bourdon PR, Xu H, et al. (1997). TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 272:32401–10
  • Chicoine E, Esteve PO, Robledo O, et al. (2002). Evidence for the role of promoter methylation in the regulation of MMP-9 gene expression. Biochem Biophys Res Commun 297:765–72
  • Chintala SK, Zhang X, Austin JS, Fini ME. (2002). Deficiency in matrix metalloproteinase gelatinase B (MMP-9) protects against retinal ganglion cell death after optic nerve ligation. J Biol Chem 277:47461–8
  • Chitwood DH, Timmermans MC. (2010). Small RNAs are on the move. Nature 467:415–19
  • Chou CS, Tai CJ, MacCalman CD, Leung PC. (2003). Dose-dependent effects of gonadotropin releasing hormone on matrix metalloproteinase (MMP)-2, and MMP-9 and tissue specific inhibitor of metalloproteinases-1 messenger ribonucleic acid levels in human decidual Stromal cells in vitro. J Clin Endocrinol Metab 88:680–8
  • Christoffersson G, Vagesjo E, Vandooren J, et al. (2012). VEGF-A recruits a proangiogenic MMP-9-delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissue. Blood 120:4653–62
  • Chung BI, Malkowicz SB, Nguyen TB, et al. (2003). Expression of the proto-oncogene Axl in renal cell carcinoma. DNA Cell Biol 22:533–40
  • Churg A, Wang R, Wang X, et al. (2007). Effect of an MMP-9/MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigs. Thorax 62:706–13
  • Cirillo N, Femiano F, Gombos F, Lanza A. (2007). Metalloproteinase 9 is the outer executioner of desmoglein 3 in apoptotic keratinocytes. Oral Dis 13:341–5
  • Clark IM, Swingler TE, Sampieri CL, Edwards DR. (2008). The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 40:1362–78
  • Collier IE, Krasnov PA, Strongin AY, et al. (1992). Alanine scanning mutagenesis and functional analysis of the fibronectin-like collagen-binding domain from human 92-kDa type IV collagenase. J Biol Chem 267:6776–81
  • Collier IE, Wilhelm SM, Eisen AZ, et al. (1988). H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J Biol Chem 263:6579–87
  • Collier IE, Legant W, Marmer B, et al. (2011). Diffusion of MMPs on the surface of collagen fibrils: the mobile cell surface-collagen substratum interface. PLoS ONE 6:e24029
  • Conidi A, Cazzola S, Beets K, et al. (2011). Few Smad proteins and many Smad-interacting proteins yield multiple functions and action modes in TGFbeta/BMP signaling in vivo. Cytokine Growth Factor Rev 22:287–300
  • Costa FF. (2007). Non-coding RNAs: lost in translation? Gene 386:1–10
  • Coussens LM, Fingleton B, Matrisian LM. (2002). Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295:2387–92
  • Coussens LM, Tinkle CL, Hanahan D, Werb Z. (2000). MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103:481–90
  • Cuenca J, Martin-Sanz P, Alvarez-Barrientos AM, et al. (2006). Infiltration of inflammatory cells plays an important role in matrix metalloproteinase expression and activation in the heart during sepsis. Am J Pathol 169:1567–76
  • Cui H, Grosso S, Schelter F, et al. (2012). On the pro-metastatic stress response to cancer therapies: evidence for a positive co-operation between TIMP-1, HIF-1alpha, and miR-210. Front Pharmacol 3:134
  • Cuzner ML, Opdenakker G. (1999). Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. J Neuroimmunol 94:1–14
  • D'Haese A, Wuyts A, Dillen C, et al. (2000). In vivo neutrophil recruitment by granulocyte chemotactic protein-2 is assisted by gelatinase B/MMP-9 in the mouse. J Interferon Cytokine Res 20:667–74
  • Daimon E, Wada Y. (2005). Role of neutrophils in matrix metalloproteinase activity in the preimplantation mouse uterus. Biol Reprod 73:163–71
  • Das A, Fernandez-Zapico ME, Cao S, et al. (2006). Disruption of an SP2/KLF6 repression complex by SHP is required for farnesoid X receptor-induced endothelial cell migration. J Biol Chem 281:39105–13
  • Das A, Yaqoob U, Mehta D, Shah VH. (2009). FXR promotes endothelial cell motility through coordinated regulation of FAK and MMP-9. Arterioscler Thromb Vasc Biol 29:562–70
  • De Munck J, Van den Steen PE, Mine A, et al. (2009). Inhibition of enzymatic degradation of adhesive-dentin interfaces. J Dent Res 88:1101–6
  • De Palma AM, Thibaut HJ, Li S, et al. (2009). Inflammatory rather than infectious insults play a role in exocrine tissue damage in a mouse model for coxsackievirus B4-induced pancreatitis. J Pathol 217:633–41
  • De Palma AM, Verbeken E, Van Aelst I, et al. (2008). Increased gelatinase B/matrix metalloproteinase 9 (MMP-9) activity in a murine model of acute coxsackievirus B4-induced pancreatitis. Virology 382:20–7
  • Dean RA, Overall CM. (2007). Proteomics discovery of metalloproteinase substrates in the cellular context by iTRAQ labeling reveals a diverse MMP-2 substrate degradome. Mol Cell Proteomics 6:611–23
  • Defawe OD, Kenagy RD, Choi C, et al. (2005). MMP-9 regulates both positively and negatively collagen gel contraction: a nonproteolytic function of MMP-9. Cardiovasc Res 66:402–9
  • Dejonckheere E, Vandenbroucke RE, Libert C. (2011). Matrix metalloproteinases as drug targets in ischemia/reperfusion injury. Drug Discov Today 16:762–78
  • Demers M, Magnaldo T, St-Pierre Y. (2005). A novel function for galectin-7: promoting tumorigenesis by up-regulating MMP-9 gene expression. Cancer Res 65:5205–10
  • Deryugina EI, Zijlstra A, Partridge JJ, et al. (2005). Unexpected effect of matrix metalloproteinase down-regulation on vascular intravasation and metastasis of human fibrosarcoma cells selected in vivo for high rates of dissemination. Cancer Res 65:10959–69
  • Descamps FJ, Kangave D, Cauwe B, et al. (2008). Interphotoreceptor retinoid-binding protein as biomarker in systemic autoimmunity with eye inflictions. J Cell Mol Med 12:2449–56
  • Descamps FJ, Martens E, Ballaux F, et al. (2004). In vivo activation of gelatinase B/MMP-9 by trypsin in acute pancreatitis is a permissive factor in streptozotocin-induced diabetes. J Pathol 204:555–61
  • Descamps FJ, Martens E, Kangave D, et al. (2006). The activated form of gelatinase B/matrix metalloproteinase-9 is associated with diabetic vitreous hemorrhage. Exp Eye Res 83:401–7
  • Descamps FJ, Martens E, Opdenakker G. (2002). Analysis of gelatinases in complex biological fluids and tissue extracts. Lab Invest 82:1607–8
  • Descamps FJ, Martens E, Proost P, et al. (2005). Gelatinase B/matrix metalloproteinase-9 provokes cataract by cleaving lens betaB1 crystallin. FASEB J 19:29–35
  • Descamps FJ, Van den Steen PE, Martens E, et al. (2003). Gelatinase B is diabetogenic in acute and chronic pancreatitis by cleaving insulin. FASEB J 17:887–9
  • Desrivieres S, Lu H, Peyri N, et al. (1993). Activation of the 92 kDa type IV collagenase by tissue kallikrein. J Cell Physiol 157:587–93
  • Dewil M, Schurmans C, Starckx S, et al. (2005). Role of matrix metalloproteinase-9 in a mouse model for amyotrophic lateral sclerosis. Neuroreport 16:321–4
  • Dogra C, Changotra H, Wedhas N, et al. (2007). TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. FASEB J 21:1857–69
  • Dolo V, D'Ascenzo S, Violini S, et al. (1999). Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro. Clin Exp Metastasis 17:131–40
  • Dolo V, Ginestra A, Ghersi G, et al. (1994). Human breast carcinoma cells cultured in the presence of serum shed membrane vesicles rich in gelatinolytic activities. J Submicrosc Cytol Pathol 26:173–80
  • Du R, Lu KV, Petritsch C, et al. (2008). HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13:206–20
  • Dubois B, Arnold B, Opdenakker G. (2000). Gelatinase B deficiency impairs reproduction. J Clin Invest 106:627–628
  • Dubois B, Masure S, Hurtenbach U, et al. (1999). Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J Clin Invest 104:1507–15
  • Dufour A, Sampson NS, Li J, et al. (2011). Small molecule anti-cancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9. Cancer Res 71:4977–88
  • Dufour A, Sampson NS, Zucker S, Cao J. (2008). Role of the hemopexin domain of matrix metalloproteinases in cell migration. J Cell Physiol 217:643–51
  • Dufour A, Zucker S, Sampson NS, et al. (2010). Role of matrix metalloproteinase-9 dimers in cell migration: design of inhibitory peptides. J Biol Chem 285:35944–56
  • Dwek RA. (1996). Glycobiology: toward understanding the function of sugars. Chem Rev 96:683–720
  • Dwivedi A, Slater SC, George SJ. (2009). MMP-9 and -12 cause N-cadherin shedding and thereby beta-catenin signalling and vascular smooth muscle cell proliferation. Cardiovasc Res 81:178–86
  • Dziembowska M, Wlodarczyk J. (2012). MMP9: a novel function in synaptic plasticity. Int J Biochem Cell Biol 44:709–13
  • Dzwonek J, Rylski M, Kaczmarek L. (2004). Matrix metalloproteinases and their endogenous inhibitors in neuronal physiology of the adult brain. FEBS Lett 567:129–35
  • Edep ME, Shirani J, Wolf P, Brown DL. (2000). Matrix metalloproteinase expression in nonrheumatic aortic stenosis. Cardiovasc Pathol 9:281–6
  • Eissa S, Ali-Labib R, Swellam M, et al. (2007). Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine. Eur Urol 52:1388–96
  • Elijovich L, Chong JY. (2010). Current and future use of intravenous thrombolysis for acute ischemic stroke. Curr Atheroscler Rep 12:316–21
  • Elkins PA, Ho YS, Smith WW, et al. (2002). Structure of the C-terminally truncated human ProMMP9, a gelatin-binding matrix metalloproteinase. Acta Crystallogr D Biol Crystallogr 58:1182–92
  • Esparza J, Kruse M, Lee J, et al. (2004). MMP-2 null mice exhibit an early onset and severe experimental autoimmune encephalomyelitis due to an increase in MMP-9 expression and activity. FASEB J 18:1682–91
  • Esparza J, Vilardell C, Calvo J, et al. (1999). Fibronectin upregulates gelatinase B (MMP-9) and induces coordinated expression of gelatinase A (MMP-2) and its activator MT1-MMP (MMP-14) by human T lymphocyte cell lines. A process repressed through RAS/MAP kinase signaling pathways. Blood 94:2754–66
  • Estella C, Herrer I, Atkinson SP, et al. (2012). Inhibition of histone deacetylase activity in human endometrial stromal cells promotes extracellular matrix remodelling and limits embryo invasion. PLoS One 7:e30508
  • Fahling M, Steege A, Perlewitz A, et al. (2005). Role of nucleolin in posttranscriptional control of MMP-9 expression. Biochim Biophys Acta 1731:32–40
  • Fang JH, Zhou HC, Zeng C, et al. (2011). MicroRNA-29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix metalloproteinase 2 expression. Hepatology 54:1729–40
  • Fang L, Teuchert M, Huber-Abel F, et al. (2010). MMP-2 and MMP-9 are elevated in spinal cord and skin in a mouse model of ALS. J Neurol Sci 294:51–6
  • Fasciglione GF, Marini S, D'Alessio S, et al. (2000). pH- and temperature-dependence of functional modulation in metalloproteinases. A comparison between neutrophil collagenase and gelatinases A and B. Biophys J 79:2138–49
  • Fayard B, Bianchi F, Dey J, et al. (2009). The serine protease inhibitor protease nexin-1 controls mammary cancer metastasis through LRP-1-mediated MMP-9 expression. Cancer Res 69:5690–8
  • Feinstein-Rotkopf Y, Arama E. (2009). Can't live without them, can live with them: roles of caspases during vital cellular processes. Apoptosis 14:980–95
  • Fernandez FG, Campbell LG, Liu W, et al. (2005). Inhibition of obliterative airway disease development in murine tracheal allografts by matrix metalloproteinase-9 deficiency. Am J Transplant 5:671–83
  • Ferry G, Lonchampt M, Pennel L, et al. (1997). Activation of MMP-9 by neutrophil elastase in an in vivo model of acute lung injury. FEBS Lett 402:111–15
  • Fiore E, Fusco C, Romero P, Stamenkovic I. (2002). Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. Oncogene 21:5213–23
  • Fiotti N, Altamura N, Fisicaro M, et al. (2006). MMP-9 microsatellite polymorphism and susceptibility to carotid arteries atherosclerosis. Arterioscler Thromb Vasc Biol 26:1330–6
  • Fligiel SE, Standiford T, Fligiel HM, et al. (2006). Matrix metalloproteinases and matrix metalloproteinase inhibitors in acute lung injury. Hum Pathol 37:422–30
  • Folkman J. (1992). The role of angiogenesis in tumor growth. Semin Cancer Biol 3:65–71
  • Fosang AJ, Neame PJ, Last K, et al. (1992). The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B. J Biol Chem 267:19470–4
  • Freskos JN, McDonald JJ, Mischke BV, et al. (1999). Synthesis and identification of conformationally constrained selective MMP inhibitors. Bioorg Med Chem Lett 9:1757–60
  • Fridman R, Toth M, Pena D, Mobashery S. (1995). Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res 55:2548–55
  • Furumoto K, Arii S, Mori A, et al. (2001). RECK gene expression in hepatocellular carcinoma: correlation with invasion-related clinicopathological factors and its clinical significance. Reverse-inducing cysteine-rich protein with Kazal motifs. Hepatology 33:189–95
  • Gaggar A, Li Y, Weathington N, Winkler M, et al. (2007). Matrix metalloprotease-9 dysregulation in lower airway secretions of cystic fibrosis patients. Am J Physiol Lung Cell Mol Physiol 293:L96–104
  • Ganor Y, Grinberg I, Reis A, et al. (2009). Human T-leukemia and T-lymphoma express glutamate receptor AMPA GluR3, and the neurotransmitter glutamate elevates the cancer-related matrix-metalloproteinases inducer CD147/EMMPRIN, MMP-9 secretion and engraftment of T-leukemia in vivo. Leuk Lymphoma 50:985–97
  • Gargioli C, Coletta M, De Grandis F, et al. (2008). PlGF-MMP-9-expressing cells restore microcirculation and efficacy of cell therapy in aged dystrophic muscle. Nat Med 14:973–8
  • Gerg M, Kopitz C, Schaten S, et al. (2008). Distinct functionality of tumor cell-derived gelatinases during formation of liver metastases. Mol Cancer Res 6:341–51
  • Geurts N, Becker-Pauly C, Martens E, et al. (2012a). Meprins process matrix metalloproteinase-9 (MMP-9)/gelatinase B and enhance the activation kinetics by MMP-3. FEBS Lett 586:4264–9
  • Geurts N, Martens E, Van Aelst I, et al. (2008). Beta-hematin interaction with the hemopexin domain of gelatinase B/MMP-9 provokes autocatalytic processing of the propeptide, thereby priming activation by MMP-3. Biochemistry 47:2689–99
  • Geurts N, Martens E, Verhenne S, et al. (2011). Insufficiently defined genetic background confounds phenotypes in transgenic studies as exemplified by malaria infection in Tlr9 knockout mice. PLoS One 6:e27131
  • Geurts N, Opdenakker G, Van den Steen PE. (2012b). Matrix metalloproteinases as therapeutic targets in protozoan parasitic infections. Pharmacol Ther 133:257–79
  • Gibson PG, Wark PA, Simpson JL, et al. (2003). Induced sputum IL-8 gene expression, neutrophil influx and MMP-9 in allergic bronchopulmonary aspergillosis. Eur Respir J 21:582–8
  • Giebel SJ, Menicucci G, McGuire PG, Das A. (2005). Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab Invest 85:597–607
  • Ginestra A, Monea S, Seghezzi G, et al. (1997). Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. J Biol Chem 272:17216–22
  • Giraudo E, Inoue M, Hanahan D. (2004). An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114:623–33
  • Gloor S, Odink K, Guenther J, et al. (1986). A glia-derived neurite promoting factor with protease inhibitory activity belongs to the protease nexins. Cell 47:687–93
  • Goldberg GI, Strongin A, Collier IE, et al. (1992). Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem 267:4583–91
  • Gong Y, Hart E, Shchurin A, Hoover-Plow J. (2008). Inflammatory macrophage migration requires MMP-9 activation by plasminogen in mice. J Clin Invest 118:3012–24
  • Gordon GM, Ledee DR, Feuer WJ, Fini ME. (2009). Cytokines and signaling pathways regulating matrix metalloproteinase-9 (MMP-9) expression in corneal epithelial cells. J Cell Physiol 221:402–11
  • Gough PJ, Gomez IG, Wille PT, Raines EW. (2006). Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J Clin Invest 116:59–69
  • Grdina DJ, Kataoka Y, Murley JS, et al. (2002). Inhibition of spontaneous metastases formation by amifostine. Int J Cancer 97:135–41
  • Greenlee KJ, Corry DB, Engler DA, et al. (2006). Proteomic identification of in vivo substrates for matrix metalloproteinases 2 and 9 reveals a mechanism for resolution of inflammation. J Immunol 177:7312–21
  • Grimson A, Farh KK, Johnston WK, et al. (2007). MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 27:91–105
  • Gschwandtner M, Purwar R, Wittmann M, et al. (2008). Histamine upregulates keratinocyte MMP-9 production via the histamine H1 receptor. J Invest Dermatol 128:2783–91
  • Gu Y, Lee HM, Sorsa T, et al. (2011). Non-antibacterial tetracyclines modulate mediators of periodontitis and atherosclerotic cardiovascular disease: a mechanistic link between local and systemic inflammation. Pharmacol Res 64:573–9
  • Gu Z, Kaul M, Yan B, et al. (2002). S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 297:1186–90
  • Gursoy-Ozdemir Y, Qiu J, Matsuoka N, et al. (2004). Cortical spreading depression activates and upregulates MMP-9. J Clin Invest 113:1447–55
  • Hahn-Dantona E, Ruiz JF, Bornstein P, Strickland DK. (2001). The low density lipoprotein receptor-related protein modulates levels of matrix metalloproteinase 9 (MMP-9) by mediating its cellular catabolism. J Biol Chem 276:15498–503
  • Hamano Y, Zeisberg M, Sugimoto H, et al. (2003). Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell 3:589–601
  • Hanahan D, Weinberg RA. (2011). Hallmarks of cancer: the next generation. Cell 144:646–74
  • Hanania R, Sun HS, Xu K, et al. (2012). Classically activated macrophages use stable microtubules for matrix metalloproteinase-9 (MMP-9) secretion. J Biol Chem 287:8468–83
  • Harris JE, Fernandez-Vilaseca M, Elkington PT, et al. (2007). IFNgamma synergizes with IL-1beta to up-regulate MMP-9 secretion in a cellular model of central nervous system tuberculosis. FASEB J 21:356–65
  • Harvima IT. (2008). Induction of matrix metalloproteinase-9 in keratinocytes by histamine. J Invest Dermatol 128:2748–50
  • Hashimoto G, Sakurai M, Teich AF, et al. (2012). 5-HT4 receptor stimulation leads to soluble a-beta-p-p-alpha production through MMP-9 Upregulation. J Alzheimers Dis 32:437–45
  • Hatipoglu S, Sevketoglu E, Gedikbasi A, et al. (2011). Urinary MMP-9/NGAL complex in children with acute cystitis. Pediatr Nephrol 26:1263–8
  • Heissig B, Hattori K, Dias S, et al. (2002). Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 109:625–37
  • Heissig B, Nishida C, Tashiro Y, et al. (2010). Role of neutrophil-derived matrix metalloproteinase-9 in tissue regeneration. Histol Histopathol 25:765–70
  • Heissig B, Rafii S, Akiyama H, et al. (2005). Low-dose irradiation promotes tissue revascularization through VEGF release from mast cells and MMP-9-mediated progenitor cell mobilization. J Exp Med 202:739–50
  • Hesek D, Toth M, Meroueh SO, et al. (2006). Design and characterization of a metalloproteinase inhibitor-tethered resin for the detection of active MMPs in biological samples. Chem Biol 13:379–86
  • Heymans S, Lupu F, Terclavers S, et al. (2005). Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. Am J Pathol 166:15–25
  • Hieronymus H, Silver PA. (2004). A systems view of mRNP biology. Genes Dev 18:2845–60
  • Hiratsuka S, Nakamura K, Iwai S, et al. (2002). MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2:289–300
  • Hirose Y, Chiba K, Karasugi T, et al. (2008). A functional polymorphism in THBS2 that affects alternative splicing and MMP binding is associated with lumbar-disc herniation. Am J Hum Genet 82:1122–9
  • Hottinger AF, Iwamoto FM, Karimi S, et al. (2011). YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma. Ann Neurol 70:163–9
  • Hozumi A, Nishimura Y, Nishiuma T, et al. (2001). Induction of MMP-9 in normal human bronchial epithelial cells by TNF-alpha via NF-kappa B-mediated pathway. Am J Physiol Lung Cell Mol Physiol 281:L1444–52
  • Hu J, Dubois V, Chaltin P, et al. (2006). Inhibition of lethal endotoxin shock with an L-pyridylalanine containing metalloproteinase inhibitor selected by high-throughput screening of a new peptide library. Comb Chem High Throughput Screen 9:599–611
  • Hu J, Fiten P, Van den Steen PE, et al. (2005a). Simulation of evolution-selected propeptide by high-throughput selection of a peptidomimetic inhibitor on a capillary DNA sequencer platform. Anal Chem 77:2116–24
  • Hu J, Van den Steen PE, Dillen C, Opdenakker G. (2005b). Targeting neutrophil collagenase/matrix metalloproteinase-8 and gelatinase B/matrix metalloproteinase-9 with a peptidomimetic inhibitor protects against endotoxin shock. Biochem Pharmacol 70:535–44
  • Hu J, Van den Steen PE, Sang QX, Opdenakker G. (2007). Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 6:480–98
  • Hua J, Muschel RJ. (1996). Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res 56:5279–84
  • Huang Z, Wang L, Meng S, et al. (2011). Berberine reduces both MMP-9 and EMMPRIN expression through prevention of p38 pathway activation in PMA-induced macrophages. Int J Cardiol 146:153–8
  • Huwiler A, Akool E-S, Aschrafi A, et al. (2003). ATP potentiates interleukin-1 beta-induced MMP-9 expression in mesangial cells via recruitment of the ELAV protein HuR. J Biol Chem 278:51758–69
  • Impola U, Uitto VJ, Hietanen J, et al. (2004). Differential expression of matrilysin-1 (MMP-7), 92 kD gelatinase (MMP-9), and metalloelastase (MMP-12) in oral verrucous and squamous cell cancer. J Pathol 202:14–22
  • Ingraham CA, Park GC, Makarenkova HP, Crossin KL. (2011). Matrix metalloproteinase (MMP)-9 induced by Wnt signaling increases the proliferation and migration of embryonic neural stem cells at low O2 levels. J Biol Chem 286:17649–57
  • Ito T, Ito M, Naito S, et al. (1999). Expression of the Axl receptor tyrosine kinase in human thyroid carcinoma. Thyroid 9:563–7
  • Itoh Y, Nagase H. (1995). Preferential inactivation of tissue inhibitor of metalloproteinases-1 that is bound to the precursor of matrix metalloproteinase 9 (progelatinase B) by human neutrophil elastase. J Biol Chem 270:16518–21
  • Itoh Y, Seiki M. (2004). MT1-MMP: an enzyme with multidimensional regulation. Trends Biochem Sci 29:285–9
  • Itoh Y, Takamura A, Ito N, et al. (2001). Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion. EMBO J 20:4782–93
  • Iyer V, Pumiglia K, DiPersio CM. (2005). Alpha3beta1 integrin regulates MMP-9 mRNA stability in immortalized keratinocytes: a novel mechanism of integrin-mediated MMP gene expression. J Cell Sci 118:1185–95
  • Jackson PL, Xu X, Wilson L, et al. (2010). Human neutrophil elastase-mediated cleavage sites of MMP-9 and TIMP-1: implications to cystic fibrosis proteolytic dysfunction. Mol Med 16:159–66
  • Jefferson T, Auf dem Keller U, Bellac C, et al. (2012). The substrate degradome of meprin metalloproteases reveals an unexpected proteolytic link between meprin beta and ADAM10. Cell Mol Life Sci 70:309–33
  • Ji RR, Xu ZZ, Wang X, Lo EH. (2009). Matrix metalloprotease regulation of neuropathic pain. Trends Pharmacol Sci 30:336–40
  • Jin DK, Shido K, Kopp HG, et al. (2006). Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med 12:557–67
  • Jin Y, Han HC, Lindsey ML. (2007). ACE inhibitors to block MMP-9 activity: new functions for old inhibitors. J Mol Cell Cardiol 43:664–6
  • Johnson JL, Dwivedi A, Somerville M, et al. (2011). Matrix metalloproteinase (MMP)-3 activates MMP-9 mediated vascular smooth muscle cell migration and neointima formation in mice. Arterioscler Thromb Vasc Biol 31:e35–44
  • Johnson S, Knox A. (1999). Autocrine production of matrix metalloproteinase-2 is required for human airway smooth muscle proliferation. Am J Physiol 277:L1109–17
  • Jorda M, Olmeda D, Vinyals A, et al. (2005). Upregulation of MMP-9 in MDCK epithelial cell line in response to expression of the Snail transcription factor. J Cell Sci 118:3371–85
  • Kamiguti AS, Lee ES, Till KJ, et al. (2004). The role of matrix metalloproteinase 9 in the pathogenesis of chronic lymphocytic leukaemia. Br J Haematol 125:128–40
  • Kaneko F, Saito H, Saito Y, et al. (2004). Down-regulation of matrix-invasive potential of human liver cancer cells by type I interferon and a histone deacetylase inhibitor sodium butyrate. Int J Oncol 24:837–45
  • Karakoc GB, Inal A, Yilmaz M, et al. (2009). Exhaled breath condensate MMP-9 levels in children with bronchiectasis. Pediatr Pulmonol 44:1010–16
  • Kessenbrock K, Plaks V, Werb Z. (2010). Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141:52–67
  • Khan MM, Simizu S, Suzuki T, et al. (2012). Protein disulfide isomerase-mediated disulfide bonds regulate the gelatinolytic activity and secretion of matrix metalloproteinase-9. Exp Cell Res 318:904–14
  • Kiaei M, Kipiani K, Calingasan NY, et al. (2007). Matrix metalloproteinase-9 regulates TNF-alpha and FasL expression in neuronal, glial cells and its absence extends life in a transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol 205:74–81
  • Kim GW, Kim HJ, Cho KJ, et al. (2009). The role of MMP-9 in integrin-mediated hippocampal cell death after pilocarpine-induced status epilepticus. Neurobiol Dis 36:169–80
  • Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N. (1993). Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 268:10425–32
  • Klein T, Bischoff R. (2011). Active metalloproteases of the A Disintegrin and Metalloprotease (ADAM) family: biological function and structure. J Proteome Res 10:17–33
  • Knauer DJ, Majumdar D, Fong PC, Knauer MF. (2000). SERPIN regulation of factor XIa. The novel observation that protease nexin 1 in the presence of heparin is a more potent inhibitor of factor XIa than C1 inhibitor. J Biol Chem 275:37340–6
  • Kobayashi T, Kishimoto J, Hattori S, et al. (2004). Matrix metalloproteinase 9 expression is coordinately modulated by the KRE-M9 and 12-O-tetradecanoyl-phorbol-13-acetate responsive elements. J Invest Dermatol 122:278–85
  • Kobayashi Y. (1997). Langerhans' cells produce type IV collagenase (MMP-9) following epicutaneous stimulation with haptens. Immunology 90:496–501
  • Koistinaho M, Malm TM, Kettunen MI, et al. (2005). Minocycline protects against permanent cerebral ischemia in wild type but not in matrix metalloprotease-9-deficient mice. J Cereb Blood Flow Metab 25:460–7
  • Kong D, Li Y, Wang Z, et al. (2007). Inhibition of angiogenesis and invasion by 3,3'-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res 67:3310–19
  • Kong MY, Li Y, Oster R, et al. (2011). Early elevation of matrix metalloproteinase-8 and -9 in pediatric ARDS is associated with an increased risk of prolonged mechanical ventilation. PLoS One 6:e22596
  • Kopitz C, Gerg M, Bandapalli OR, et al. (2007). Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. Cancer Res 67:8615–23
  • Kotra LP, Zhang L, Fridman R, et al. (2002). N-Glycosylation pattern of the zymogenic form of human matrix metalloproteinase-9. Bioorg Chem 30:356–70
  • Kowluru RA, Zhong Q, Santos JM. (2012). Matrix metalloproteinases in diabetic retinopathy: potential role of MMP-9. Expert Opin Investig Drugs 21:797–805
  • Kridel SJ, Chen E, Kotra LP, et al. (2001). Substrate hydrolysis by matrix metalloproteinase-9. J Biol Chem 276:20572–8
  • Krüger A, Kates RE, Edwards DR. (2010). Avoiding spam in the proteolytic internet: future strategies for anti-metastatic MMP inhibition. Biochim Biophys Acta 1803:95–102
  • Krüger A, Sanchez-Sweatman OH, Martin DC, et al. (1998). Host TIMP-1 overexpression confers resistance to experimental brain metastasis of a fibrosarcoma cell line. Oncogene 16:2419–23
  • Kuljaca S, Liu T, Tee AE, et al. (2007). Enhancing the anti-angiogenic action of histone deacetylase inhibitors. Mol Cancer 6:68
  • Kumar B, Koul S, Petersen J, et al. (2010). p38 mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity. Cancer Res 70:832–41
  • Kyriakides TR, Wulsin D, Skokos EA, et al. (2009). Mice that lack matrix metalloproteinase-9 display delayed wound healing associated with delayed reepithelization and disordered collagen fibrillogenesis. Matrix Biol 28:65–73
  • Labrie M, St-Pierre Y. (2012). Epigenetic regulation of mmp-9 gene expression. Cell Mol Life Sci . DOI: 10.1007/s00018-012-1214-z
  • Lakka SS, Gondi CS, Yanamandra N, et al. (2004). Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 23:4681–9
  • Lakka SS, Jasti SL, Gondi C, et al. (2002a). Downregulation of MMP-9 in ERK-mutated stable transfectants inhibits glioma invasion in vitro. Oncogene 21:5601–8
  • Lakka SS, Rajan M, Gondi C, et al. (2002b). Adenovirus-mediated expression of antisense MMP-9 in glioma cells inhibits tumor growth and invasion. Oncogene 21:8011–19
  • Lamar JM, Iyer V, DiPersio CM. (2008a). Integrin alpha3beta1 potentiates TGFbeta-mediated induction of MMP-9 in immortalized keratinocytes. J Invest Dermatol 128:575–86
  • Lamar JM, Pumiglia KM, DiPersio CM. (2008b). An immortalization-dependent switch in integrin function up-regulates MMP-9 to enhance tumor cell invasion. Cancer Res 68:7371–9
  • Lambert V, Wielockx B, Munaut C, et al. (2003). MMP-2 and MMP-9 synergize in promoting choroidal neovascularization. FASEB J 17:2290–2
  • Lamblin N, Bauters C, Hermant X, et al. (2002). Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease. J Am Coll Cardiol 40:43–8
  • Lanchou J, Corbel M, Tanguy M, et al. (2003). Imbalance between matrix metalloproteinases (MMP-9 and MMP-2) and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in acute respiratory distress syndrome patients. Crit Care Med 31:536–42
  • Lau WC, Rubinstein JL. (2012). Subnanometre-resolution structure of the intact Thermus thermophilus H+-driven ATP synthase. Nature 481:214–18
  • Lauer-Fields JL, Whitehead JK, Li S, et al. (2008). Selective modulation of matrix metalloproteinase 9 (MMP-9) functions via exosite inhibition. J Biol Chem 283:20087–95
  • Lauhio A, Sorsa T, Srinivas R, et al. (2008). Urinary matrix metalloproteinase -8, -9, -14 and their regulators (TRY-1, TRY-2, TATI) in patients with diabetic nephropathy. Ann Med 40:312–20
  • Lausch E, Keppler R, Hilbert K, et al. (2009). Mutations in MMP9 and MMP13 determine the mode of inheritance and the clinical spectrum of metaphyseal anadysplasia. Am J Hum Genet 85:168–78
  • Lee CS, Kwon YW, Yang HM, et al. (2009). New mechanism of rosiglitazone to reduce neointimal hyperplasia: activation of glycogen synthase kinase-3beta followed by inhibition of MMP-9. Arterioscler Thromb Vasc Biol 29:472–9
  • Lee JH, Welch DR. (1997). Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene, KiSS-1. Cancer Res 57:2384–7
  • Lee KH, Choi EY, Kim MK, et al. (2010). Inhibition of histone deacetylase activity down-regulates urokinase plasminogen activator and matrix metalloproteinase-9 expression in gastric cancer. Mol Cell Biochem 343:163–71
  • Lee Y, Fryer JD, Kang H, et al. (2011). ATXN1 protein family and CIC regulate extracellular matrix remodeling and lung alveolarization. Dev Cell 21:746–57
  • Letellier E, Kumar S, Sancho-Martinez I, et al. (2010). CD95-ligand on peripheral myeloid cells activates Syk kinase to trigger their recruitment to the inflammatory site. Immunity 32:240–52
  • Lewis BP, Burge CB, Bartel DP. (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120:15–20
  • Li H, Mittal A, Paul PK, Kumar M, et al. (2009). Tumor necrosis factor-related weak inducer of apoptosis augments matrix metalloproteinase 9 (MMP-9) production in skeletal muscle through the activation of nuclear factor-kappaB-inducing kinase and p38 mitogen-activated protein kinase: a potential role of MMP-9 in myopathy. J Biol Chem 284:4439–50
  • Li N, Wang HX, Zhang J, et al. (2012). KISS-1 inhibits the proliferation and invasion of gastric carcinoma cells. World J Gastroenterol 18:1827–33
  • Li W, Challis JR. (2005). Corticotropin-releasing hormone and urocortin induce secretion of matrix metalloproteinase-9 (MMP-9) without change in tissue inhibitors of MMP-1 by cultured cells from human placenta and fetal membranes. J Clin Endocrinol Metab 90:6569–74
  • Lijnen HR. (2001). Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 86:324–33
  • Lijnen HR, Silence J, Van Hoef B., Collen D. (1998). Stromelysin-1 (MMP-3)-independent gelatinase expression and activation in mice. Blood 91:2045–53
  • Lim GP, Vu TH, Werb Z, et al. (1998). MMP-9 (Gelatinase B) knockout mice demonstrate impaired learning and behavior. Society for Neuroscience Abstracts 24:1748–1748
  • Lingwal N, Padmasekar M, Samikannu B, et al. (2012). Inhibition of gelatinase B (matrix metalloprotease-9) activity reduces cellular inflammation and restores function of transplanted pancreatic islets. Diabetes 61:2045–53
  • Liu J, van Mil A, Aguor EN, et al. (2012). MiR-155 inhibits cell migration of human cardiomyocyte progenitor cells (hCMPCs) via targeting of MMP-16. J Cell Mol Med 16:2379–86
  • Liu X, Lee DJ, Skittone LK, et al. (2010). Role of gelatinases in disuse-induced skeletal muscle atrophy. Muscle Nerve 41:174–8
  • Liu Z, Li N, Diaz LA, et al. (2005). Synergy between a plasminogen cascade and MMP-9 in autoimmune disease. J Clin Invest 115:879–87
  • Liu Z, Shipley JM, Vu TH, et al. (1998). Gelatinase B-deficient mice are resistant to experimental bullous pemphigoid. J Exp Med 188:475–82
  • Liu Z, Zhou X, Shapiro SD, et al. (2000). The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell 102:647–55
  • Lorenzl S, Narr S, Angele B, et al. (2006). The matrix metalloproteinases inhibitor Ro 28–2653 [correction of Ro 26–2853] extends survival in transgenic ALS mice. Exp Neurol 200:166–71
  • MacLauchlan S, Skokos EA, Meznarich N, et al. (2009). Macrophage fusion, giant cell formation, and the foreign body response require matrix metalloproteinase 9. J Leukoc Biol 85:617–26
  • Maeshima Y, Sudhakar A, Lively JC, et al. (2002). Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 295:140–3
  • Maglott D, Ostell J, Pruitt KD, Tatusova T. (2011). Entrez Gene: gene-centered information at NCBI. Nucleic Acids Res 39:D52–7
  • Major TC, Liang L, Lu X, et al. (2002). Extracellular matrix metalloproteinase inducer (EMMPRIN) is induced upon monocyte differentiation and is expressed in human atheroma. Arterioscler Thromb Vasc Biol 22:1200–7
  • Malla N, Berg E, Uhlin-Hansen L, Winberg JO. (2008). Interaction of pro-matrix metalloproteinase-9/proteoglycan heteromer with gelatin and collagen. J Biol Chem 283:13652–65
  • Manabe S, Gu Z, Lipton SA. (2005). Activation of matrix metalloproteinase-9 via neuronal nitric oxide synthase contributes to NMDA-induced retinal ganglion cell death. Invest Ophthalmol Vis Sci 46:4747–53
  • Maolood N, Hardin-Pouzet H, Grange-Messent V. (2008). Matrix metalloproteinases MMP2 and MMP9 are upregulated by noradrenaline in the mouse neuroendocrine hypothalamus. Eur J Neurosci 27:1143–52
  • Martens E, Leyssen A, Van Aelst I, et al. (2007). A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains. Biochim Biophys Acta 1770:178–86
  • Martin MD, Carter KJ, Jean-Philippe SR, et al. (2008). Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background. Cancer Res 68:6251–9
  • Martinez-Hernandez MG, Baiza-Gutman LA, Castillo-Trapala A, Armant DR. (2011). Regulation of proteinases during mouse peri-implantation development: urokinase-type plasminogen activator expression and cross talk with matrix metalloproteinase 9. Reproduction 141:227–39
  • Marx N, Froehlich J, Siam L, Ittner J, et al. (2003). Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 23:283–8
  • Mason DP, Kenagy RD, Hasenstab D, et al. (1999). Matrix metalloproteinase-9 overexpression enhances vascular smooth muscle cell migration and alters remodeling in the injured rat carotid artery. Circ Res 85:1179–85
  • Masson V, de la Ballina LR, Munaut C, et al. (2005). Contribution of host MMP-2 and MMP-9 to promote tumor vascularization and invasion of malignant keratinocytes. FASEB J 19:234–6
  • Massova I, Kotra LP, Fridman R, Mobashery S. (1998). Matrix metalloproteinases: structures, evolution, and diversification. FASEB J 12:1075–95
  • Masure S, Billiau A, Van Damme J, Opdenakker G. (1990). Human hepatoma cells produce an 85 kDa gelatinase regulated by phorbol 12-myristate 13-acetate. Biochim Biophys Acta 1054:317–25
  • Masure S, Nys G, Fiten P, et al. (1993). Mouse gelatinase B. cDNA cloning, regulation of expression and glycosylation in WEHI-3 macrophages and gene organisation. Eur J Biochem 218:129–41
  • Masure S, Proost P, Van Damme J, Opdenakker G. (1991). Purification and identification of 91-kDa neutrophil gelatinase. Release by the activating peptide interleukin-8. Eur J Biochem 198:391–8
  • Matsumoto Y, Park IK, Kohyama K. (2009). Matrix metalloproteinase (MMP)-9, but not MMP-2, is involved in the development and progression of C protein-induced myocarditis and subsequent dilated cardiomyopathy. J Immunol 183:4773–81
  • Mattu TS, Royle L, Langridge J, et al. (2000). O-glycan analysis of natural human neutrophil gelatinase B using a combination of normal phase-HPLC and online tandem mass spectrometry: implications for the domain organization of the enzyme. Biochemistry 39:15695–704
  • Mayo MW, Denlinger CE, Broad RM, et al. (2003). Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway. J Biol Chem 278:18980–89
  • McMillan SJ, Kearley J, Campbell JD, et al. (2004). Matrix metalloproteinase-9 deficiency results in enhanced allergen-induced airway inflammation. J Immunol 172:2586–94
  • Mehta PB, Jenkins BL, McCarthy L, et al. (2003). MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene 22:1381–9
  • Meighan PC, Meighan SE, Rich ED, et al. (2012). Matrix metalloproteinase-9 and -2 enhance the ligand sensitivity of photoreceptor cyclic nucleotide-gated channels. Channels (Austin) 6:181–96
  • Melani C, Sangaletti S, Barazzetta FM, et al. (2007). Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res 67:11438–46
  • Melaragno MG, Fridell YW, Berk BC. (1999). The Gas6/Axl system: a novel regulator of vascular cell function. Trends Cardiovasc Med 9:250–3
  • Meli DN, Christen S, Leib SL. (2003). Matrix metalloproteinase-9 in pneumococcal meningitis: activation via an oxidative pathway. J Infect Dis 187:1411–15
  • Metz LM, Li D, Traboulsee A, et al. (2009). Glatiramer acetate in combination with minocycline in patients with relapsing–remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial. Mult Scler 15:1183–94
  • Michaluk P, Kolodziej L, Mioduszewska B, et al. (2007). Beta-dystroglycan as a target for MMP-9, in response to enhanced neuronal activity. J Biol Chem 282:16036–41
  • Michaluk P, Wawrzyniak M, Alot P, et al. (2011). Influence of matrix metalloproteinase MMP-9 on dendritic spine morphology. J Cell Sci 124:3369–80
  • Miller JP, Holcomb J, Al-Ramahi I, et al. (2010). Matrix metalloproteinases are modifiers of huntingtin proteolysis and toxicity in Huntington's disease. Neuron 67:199–212
  • Minasi MG, Riminucci M, De Angelis L, et al. (2002). The meso-angioblast: a multipotent, self-renewing cell that originates from the dorsal aorta and differentiates into most mesodermal tissues. Development 129:2773–83
  • Miranda KC, Huynh T, Tay Y, et al. (2006). A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 126:1203–17
  • Mitmaker EJ, Griff NJ, Grogan RH, et al. (2011). Modulation of matrix metalloproteinase activity in human thyroid cancer cell lines using demethylating agents and histone deacetylase inhibitors. Surgery 149:504–11
  • Moazed D. (2009). Small RNAs in transcriptional gene silencing and genome defence. Nature 457:413–20
  • Mohan R, Chintala SK, Jung JC, et al. (2002). Matrix metalloproteinase gelatinase B (MMP-9) coordinates and effects epithelial regeneration. J Biol Chem 277:2065–72
  • Molica S, Vitelli G, Levato D, et al. (2003). Increased serum levels of matrix metalloproteinase-9 predict clinical outcome of patients with early B-cell chronic lymphocytic leukaemia. Eur J Haematol 70:373–8
  • Monferran S, Paupert J, Dauvillier S, et al. (2004). The membrane form of the DNA repair protein Ku interacts at the cell surface with metalloproteinase 9. EMBO J 23:3758–68
  • Moore BA, Manthey CL, Johnson DL, Bauer AJ. (2011). Matrix metalloproteinase-9 inhibition reduces inflammation and improves motility in murine models of postoperative ileus. Gastroenterology 141:1283–92
  • Moore CS, Crocker SJ. (2012). An alternate perspective on the roles of TIMPs and MMPs in pathology. Am J Pathol 180:12–16
  • Morgan AR, Zhang B, Tapper W, et al. (2003). Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease. J Mol Med (Berl) 81:321–6
  • Morgan MR, Thomas GJ, Russell A, et al. (2004). The integrin cytoplasmic-tail motif EKQKVDLSTDC is sufficient to promote tumor cell invasion mediated by matrix metalloproteinase (MMP)-2 or MMP-9. J Biol Chem 279:26533–9
  • Moses MA, Wiederschain D, Loughlin KR, et al. (1998). Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 58:1395–9
  • Muroski ME, Roycik MD, Newcomer RG, et al. (2008). Matrix metalloproteinase-9/gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis. Curr Pharm Biotechnol 9:34–46
  • Murphy G. (2008). The ADAMs: signalling scissors in the tumour microenvironment. Nat Rev Cancer 8:929–41
  • Murphy G, Crabbe T. (1995). Gelatinases A and B. Methods Enzymol 248:470–84
  • Murphy G, Murthy A, Khokha R. (2008). Clipping, shedding and RIPping keep immunity on cue. Trends Immunol 29:75–82
  • Nabeshima K, Iwasaki H, Koga K, et al. (2006). Emmprin (basigin/CD147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol Int 56:359–67
  • Nagase H, Visse R, Murphy G. (2006). Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69:562–73
  • Nagase H, Woessner JF. (1999). Matrix metalloproteinases. J Biol Chem 274:21491–4
  • Nair RR, Solway J, Boyd DD. (2006). Expression cloning identifies transgelin (SM22) as a novel repressor of 92-kDa type IV collagenase (MMP-9) expression. J Biol Chem 281:26424–36
  • Nakamaru Y, Vuppusetty C, Wada H, et al. (2009). A protein deacetylase SIRT1 is a negative regulator of metalloproteinase-9. FASEB J 23:2810–19
  • Nakasone ES, Askautrud HA, Kees T, et al. (2012). Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 21:488–503
  • Nee LE, McMorrow T, Campbell E, et al. (2004). TNF-alpha and IL-1beta-mediated regulation of MMP-9 and TIMP-1 in renal proximal tubular cells. Kidney Int 66:1376–86
  • Nielsen BS, Timshel S, Kjeldsen L, et al. (1996). 92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. Int J Cancer 65:57–62
  • Nordon IM, Hinchliffe RJ, Loftus IM, Thompson MM. (2011). Pathophysiology and epidemiology of abdominal aortic aneurysms. Nat Rev Cardiol 8:92–102
  • Nosaka M, Ishida Y, Kimura A, et al. (2011). Absence of IFN-gamma accelerates thrombus resolution through enhanced MMP-9 and VEGF expression in mice. J Clin Invest 121:2911–20
  • Nubling G, Levin J, Bader B, et al. (2012). Limited cleavage of tau with matrix-metalloproteinase MMP-9, but not MMP-3, enhances tau oligomer formation. Exp Neurol 237:470–6
  • Nyman JS, Lynch CC, Perrien DS, et al. (2011). Differential effects between the loss of MMP-2 and MMP-9 on structural and tissue-level properties of bone. J Bone Miner Res 26:1252–60
  • O'Connell JP, Willenbrock F, Docherty AJ, et al. (1994). Analysis of the role of the COOH-terminal domain in the activation, proteolytic activity, and tissue inhibitor of metalloproteinase interactions of gelatinase B. J Biol Chem 269:14967–73
  • O'Farrell TJ, Pourmotabbed T. (2000). Identification of structural elements important for matrix metalloproteinase type V collagenolytic activity as revealed by chimeric enzymes. Role of fibronectin-like domain and active site of gelatinase B. J Biol Chem 275:27964–72
  • O'Reilly MS, Boehm T, Shing Y, et al. (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277–85
  • Ogata Y, Enghild JJ, Nagase H. (1992). Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem 267:3581–84
  • Oh J, Takahashi R, Kondo S, et al. (2001). The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 107:789–800
  • Okada Y, Gonoji Y, Naka K, et al. (1992). Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymic properties. J Biol Chem 267:21712–19
  • Okamoto T, Akaike T, Sawa T, et al. (2001). Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J Biol Chem 276:29596–602
  • Okuducu AF, Zils U, Michaelis SA, et al. (2006). Increased expression of avian erythroblastosis virus E26 oncogene homolog 1 in World Health Organization grade 1 meningiomas is associated with an elevated risk of recurrence and is correlated with the expression of its target genes matrix metalloproteinase-2 and MMP-9. Cancer 107:1365–72
  • Okulski P, Jay TM, Jaworski J, et al. (2007). TIMP-1 abolishes MMP-9-dependent long-lasting long-term potentiation in the prefrontal cortex. Biol Psychiatry 62:359–62
  • Olson MW, Bernardo MM, Pietila M, et al. (2000). Characterization of the monomeric and dimeric forms of latent and active matrix metalloproteinase-9. Differential rates for activation by stromelysin 1. J Biol Chem 275:2661–8
  • Opdenakker G, Masure S, Grillet B, Van Damme J. (1991a). Cytokine-mediated regulation of human leukocyte gelatinases and role in arthritis. Lymphokine Cytokine Res 10:317–24
  • Opdenakker G, Masure S, Proost P, et al. (1991b). Natural human monocyte gelatinase and its inhibitor. FEBS Lett 284:73–8
  • Opdenakker G, Nelissen I, Van Damme J. (2003). Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis. Lancet Neurol 2:747–56
  • Opdenakker G, Van Damme J. (1994). Cytokine-regulated proteases in autoimmune diseases. Immunol Today 15:103–7
  • Opdenakker G, Van Damme J. (2011). Probing cytokines, chemokines and matrix metalloproteinases towards better immunotherapies of multiple sclerosis. Cytokine Growth Factor Rev 22:359–65
  • Opdenakker G, Van den Steen PE, Dubois B, et al. (2001a). Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol 69:851–9
  • Opdenakker G, Van den Steen PE, Van Damme J. (2001b). Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol 22:571–9
  • Ortega N, Behonick DJ, Werb Z. (2004). Matrix remodeling during endochondral ossification. Trends Cell Biol 14:86–93
  • Ortega N, Wang K, Ferrara N, et al. (2010). Complementary interplay between matrix metalloproteinase-9, vascular endothelial growth factor and osteoclast function drives endochondral bone formation. Dis Model Mech 3:224–35
  • Osaki M, Takeshita F, Sugimoto Y, et al. (2011). MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease-13 expression. Mol Ther 19:1123–30
  • Overall CM, Butler GS. (2007). Protease yoga: extreme flexibility of a matrix metalloproteinase. Structure 15:1159–61
  • Overall CM, Dean RA. (2006). Degradomics: systems biology of the protease web. Pleiotropic roles of MMPs in cancer. Cancer Metastasis Rev 25:69–75
  • Overall CM, Kleifeld O. (2006). Tumour microenvironment – opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 6:227–39
  • Overall CM, Lopez-Otin C. (2002). Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2:657–72
  • Overall CM, Tam EM, Kappelhoff R, et al. (2004). Protease degradomics: mass spectrometry discovery of protease substrates and the CLIP-CHIP, a dedicated DNA microarray of all human proteases and inhibitors. Biol Chem 385:493–504
  • Owen CA, Hu Z, Barrick B, Shapiro SD. (2003). Inducible expression of tissue inhibitor of metalloproteinases-resistant matrix metalloproteinase-9 on the cell surface of neutrophils. Am J Respir Cell Mol Biol 29:283–94
  • Paemen L, Martens E, Norga K, et al. (1996). The gelatinase inhibitory activity of tetracyclines and chemically modified tetracycline analogues as measured by a novel microtiter assay for inhibitors. Biochem Pharmacol 52:105–11
  • Page K, Ledford JR, Zhou P, Wills-Karp M. (2009). A TLR2 agonist in German cockroach frass activates MMP-9 release and is protective against allergic inflammation in mice. J Immunol 183:3400–8
  • Paquette B, Bisson M, Therriault H, et al. (2003). Activation of matrix metalloproteinase-2 and -9 by 2- and 4-hydroxyestradiol. J Steroid Biochem Mol Biol 87:65–73
  • Park SY, Jeong KJ, Panupinthu N, et al. (2011). Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression. Oncogene 30:1351–9
  • Parks WC, Wilson CL, Lopez-Boado YS. (2004). Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 4:617–29
  • Parmo-Cabanas M, Molina-Ortiz I, Matias-Roman S, et al. (2006). Role of metalloproteinases MMP-9 and MT1-MMP in CXCL12-promoted myeloma cell invasion across basement membranes. J Pathol 208:108–18
  • Paupert J, Mansat-De Mas V, Demur C, et al. (2008). Cell-surface MMP-9 regulates the invasive capacity of leukemia blast cells with monocytic features. Cell Cycle 7:1047–53
  • Pei P, Horan MP, Hille R, et al. (2006). Reduced nonprotein thiols inhibit activation and function of MMP-9: implications for chemoprevention. Free Radic Biol Med 41:1315–24
  • Pelegrina LT, Lombardi MG, Fiszman GL, et al. (2012). Immunoglobulin G from breast cancer patients regulates MCF-7 cells migration and MMP-9 activity by stimulating muscarinic acetylcholine receptors. J Clin Immunol. DOI: 10.1007/s10875-012-9804-y
  • Pellikainen JM, Ropponen KM, Kataja VV, et al. (2004). Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 10:7621–8
  • Pelus LM, Bian H, King AG, Fukuda S. (2004). Neutrophil-derived MMP-9 mediates synergistic mobilization of hematopoietic stem and progenitor cells by the combination of G-CSF and the chemokines GRObeta/CXCL2 and GRObetaT/CXCL2delta4. Blood 103:110–19
  • Peppin GJ, Weiss SJ. (1986). Activation of the endogenous metalloproteinase, gelatinase, by triggered human neutrophils. Proc Natl Acad Sci USA 83:4322–6
  • Pflugfelder SC, Farley W, Luo L, et al. (2005). Matrix metalloproteinase-9 knockout confers resistance to corneal epithelial barrier disruption in experimental dry eye. Am J Pathol 166:61–71
  • Piao S, Zhao S, Guo F, et al. (2012). Increased expression of CD147 and MMP-9 is correlated with poor prognosis of salivary duct carcinoma. J Cancer Res Clin Oncol 138:627–35
  • Piccard H, Muschel RJ, Opdenakker G. (2012). On the dual roles and polarized phenotypes of neutrophils in tumor development and progression. Crit Rev Oncol Hematol 82:296–309
  • Piccard H, Van den Steen PE, Opdenakker G. (2007). Hemopexin domains as multifunctional liganding modules in matrix metalloproteinases and other proteins. J Leukoc Biol 81:870–92
  • Porter KE, Naik J, Turner NA, et al. (2002). Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration. J Vasc Surg 36:150–7
  • Porter KE, Turner NA, O'Regan DJ, Ball SG. (2004). Tumor necrosis factor alpha induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin. Cardiovasc Res 64:507–15
  • Pourmotabbed T. (1994). Relation between substrate specificity and domain structure of 92-kDa type IV collagenase. Ann N Y Acad Sci 732:372–4
  • Profita M, Gagliardo R, Di Giorgi R, et al. (2004). In vitro effects of flunisolide on MMP-9, TIMP-1, fibronectin, TGF-beta1 release and apoptosis in sputum cells freshly isolated from mild to moderate asthmatics. Allergy 59:927–32
  • Proost P, Van Damme J, Opdenakker G. (1993). Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem Biophys Res Commun 192:1175–81
  • Provatopoulou X, Gounaris A, Kalogera E, et al. (2009). Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast cancer disease. BMC Cancer 9:390
  • Prudova A, Auf dem Keller U, Butler GS, Overall CM. (2010). Multiplex N-terminome analysis of MMP-2 and MMP-9 substrate degradomes by iTRAQ-TAILS quantitative proteomics. Mol Cell Proteomics 9:894–911
  • Pruijt JF, Fibbe WE, Laterveer L, et al. (1999). Prevention of interleukin-8-induced mobilization of hematopoietic progenitor cells in rhesus monkeys by inhibitory antibodies against the metalloproteinase gelatinase B (MMP-9). Proc Natl Acad Sci USA 96:10863–8
  • Pruijt JF, Verzaal P, van Os R, et al. (2002). Neutrophils are indispensable for hematopoietic stem cell mobilization induced by interleukin-8 in mice. Proc Natl Acad Sci USA 99:6228–33
  • Purwar R, Kraus M, Werfel T, Wittmann M. (2008). Modulation of keratinocyte-derived MMP-9 by IL-13: a possible role for the pathogenesis of epidermal inflammation. J Invest Dermatol 128:59–66
  • Qiu Z, Hu J, Van den Steen PE, Opdenakker G. (2012a). Targeting matrix metalloproteinases in acute inflammatory shock syndromes. Comb Chem High Throughput Screen 15:555–70
  • Qiu Z, Yan M, Li Q, et al. (2012b). Definition of peptide inhibitors from a synthetic peptide library by targeting gelatinase B/matrix metalloproteinase-9 (MMP-9) and TNF-alpha converting enzyme (TACE/ADAM-17). J Enzyme Inhib Med Chem 27:533–40
  • Quiney C, Billard C, Faussat AM, et al. (2006a). Pro-apoptotic properties of hyperforin in leukemic cells from patients with B-cell chronic lymphocytic leukemia. Leukemia 20:491–7
  • Quiney C, Billard C, Mirshahi P, et al. (2006b). Hyperforin inhibits MMP-9 secretion by B-CLL cells and microtubule formation by endothelial cells. Leukemia 20:583–9
  • Radisky DC, Bissell MJ. (2004). Cancer. Respect thy neighbor! Science 303:775–7
  • Rajapakse N, Kim MM, Mendis E, et al. (2006). Carboxylated chitooligosaccharides (CCOS) inhibit MMP-9 expression in human fibrosarcoma cells via down-regulation of AP-1. Biochim Biophys Acta 1760:1780–8
  • Ram M, Sherer Y, Shoenfeld Y. (2006). Matrix metalloproteinase-9 and autoimmune diseases. J Clin Immunol 26:299–307
  • Ramachandran GN, Kartha G. (1954). Structure of collagen. Nature 174:269–70
  • Ramani VC, Kaushal GP, Haun RS. (2011). Proteolytic action of kallikrein-related peptidase 7 produces unique active matrix metalloproteinase-9 lacking the C-terminal hemopexin domains. Biochim Biophys Acta 1813:1525–31
  • Ranuncolo SM, Matos E, Loria D, et al. (2002). Circulating 92-kilodalton matrix metalloproteinase (MMP-9) activity is enhanced in the euglobulin plasma fraction of head and neck squamous cell carcinoma. Cancer 94:1483–91
  • Rao JS, Bhoopathi P, Chetty C, et al. (2007). MMP-9 short interfering RNA induced senescence resulting in inhibition of medulloblastoma growth via p16(INK4a) and mitogen-activated protein kinase pathway. Cancer Res 67:4956–64
  • Rao JS, Gondi C, Chetty C, et al. (2005). Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non-small cell lung cancer cells. Mol Cancer Ther 4:1399–408
  • Rawlings ND, Barrett AJ, Bateman A. (2010). MEROPS: the peptidase database. Nucleic Acids Res 38:D227–33
  • Redondo-Munoz J, Escobar-Diaz E, Samaniego R, et al. (2006). MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by alpha4beta1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration. Blood 108:3143–51
  • Redondo-Munoz J, Ugarte-Berzal E, Garcia-Marco JA, et al. (2008). Alpha4beta1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. Blood 112:169–78
  • Redondo-Munoz J, Ugarte-Berzal E, Terol MJ, et al. (2010). Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia B cell survival through its hemopexin domain. Cancer Cell 17:160–72
  • Renckens R, Roelofs JJ, Florquin S, et al. (2006). Matrix metalloproteinase-9 deficiency impairs host defense against abdominal sepsis. J Immunol 176:3735–41
  • Reponen P, Sahlberg C, Munaut C, et al. (1994). High expression of 92-kD type IV collagenase (gelatinase B) in the osteoclast lineage during mouse development. J Cell Biol 124:1091–102
  • Rhee JS, Coussens LM. (2002). RECKing MMP function: implications for cancer development. Trends Cell Biol 12:209–11
  • Ringshausen I, Dechow T, Schneller F, et al. (2004). Constitutive activation of the MAPkinase p38 is critical for MMP-9 production and survival of B-CLL cells on bone marrow stromal cells. Leukemia 18:1964–70
  • Robertson L, Grip L, Mattsson HL, et al. (2007). Release of protein as well as activity of MMP-9 from unstable atherosclerotic plaques during percutaneous coronary intervention. J Intern Med 262:659–67
  • Robinson SN, Pisarev VM, Chavez JM, et al. (2003). Use of matrix metalloproteinase (MMP)-9 knockout mice demonstrates that MMP-9 activity is not absolutely required for G-CSF or Flt-3 ligand-induced hematopoietic progenitor cell mobilization or engraftment. Stem Cells 21:417–27
  • Roeb E, Schleinkofer K, Kernebeck T, et al. (2002). The matrix metalloproteinase 9 (mmp-9) hemopexin domain is a novel gelatin binding domain and acts as an antagonist. J Biol Chem 277:50326–32
  • Rosell A, Alvarez-Sabin J, Arenillas JF, et al. (2005). A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke. Stroke 36:1415–20
  • Rosell A, Cuadrado E, Ortega-Aznar A, et al. (2008). MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke 39:1121–6
  • Rosenblum G, Meroueh S, Toth M, et al. (2007a). Molecular structures and dynamics of the stepwise activation mechanism of a matrix metalloproteinase zymogen: challenging the cysteine switch dogma. J Am Chem Soc 129:13566–74
  • Rosenblum G, Van den Steen PE, Cohen SR, et al. (2010). Direct visualization of protease action on collagen triple helical structure. PLoS One 5:e11043
  • Rosenblum G, Van den Steen PE, Cohen SR, et al. (2007b). Insights into the structure and domain flexibility of full-length pro-matrix metalloproteinase-9/gelatinase B. Structure 15:1227–36
  • Rowsell S, Hawtin P, Minshull CA, et al. (2002). Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor. J Mol Biol 319:173–81
  • Roy JS, Van Themsche C, Demers M, et al. (2007). Triggering of T-cell leukemia and dissemination of T-cell lymphoma in MMP-9-deficient mice. Leukemia 21:2506–11
  • Rudd PM, Mattu TS, Masure S, et al. (1999). Glycosylation of natural human neutrophil gelatinase B and neutrophil gelatinase B-associated lipocalin. Biochemistry 38:13937–50
  • Rush TS, Powers R. (2004). The application of X-ray, NMR, and molecular modeling in the design of MMP inhibitors. Curr Top Med Chem 4:1311–27
  • Saffarian S, Collier IE, Marmer BL, et al. (2004). Interstitial collagenase is a Brownian ratchet driven by proteolysis of collagen. Science 306:108–11
  • Sakata K, Satoh M, Someya M, et al. (2004). Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-Hodgkin lymphoma. Cancer 100:356–65
  • Salo T, Lyons JG, Rahemtulla F, et al. (1991). Transforming growth factor-beta 1 up-regulates type IV collagenase expression in cultured human keratinocytes. J Biol Chem 266:11436–41
  • Salo T, Soini Y, Oiva J, et al. (2006). Chemically modified tetracyclines (CMT-3 and CMT-8) enable control of the pathologic remodellation of human aortic valve stenosis via MMP-9 and VEGF inhibition. Int J Cardiol 111:358–64
  • Sampaolesi M, Blot S, D'Antona G, et al. (2006). Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 444:574–9
  • Sampaolesi M, Torrente Y, Innocenzi A, et al. (2003). Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. Science 301:487–92
  • Sato N, Maehara N, Su GH, Goggins M. (2003). Effects of 5-aza-2′-deoxycytidine on matrix metalloproteinase expression and pancreatic cancer cell invasiveness. J Natl Cancer Inst 95:327–30
  • Satta J, Oiva J, Salo T, et al. (2003). Evidence for an altered balance between matrix metalloproteinase-9 and its inhibitors in calcific aortic stenosis. Ann Thorac Surg 76:681–8
  • Sbai O, Ould-Yahoui A, Ferhat L, et al. (2010). Differential vesicular distribution and trafficking of MMP-2, MMP-9, and their inhibitors in astrocytes. Glia 58:344–66
  • Sbardella D, Inzitari R, Iavarone F, et al. (2012). Enzymatic processing by MMP-2 and MMP-9 of wild-type and mutated mouse beta-dystroglycan. IUBMB Life 64:988–94
  • Schilling O, Overall CM. (2008). Proteome-derived, database-searchable peptide libraries for identifying protease cleavage sites. Nat Biotechnol 26:685–94
  • Schonbeck U, Mach F, Libby P. (1998). Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol 161:3340–6
  • Schroer N, Pahne J, Walch B, et al. (2011). Molecular pathobiology of human cervical high-grade lesions: paracrine STAT3 activation in tumor-instructed myeloid cells drives local MMP-9 expression. Cancer Res 71:87–97
  • Schwartz B, Melnikova VO, Tellez C, et al. (2007). Loss of AP-2alpha results in deregulation of E-cadherin and MMP-9 and an increase in tumorigenicity of colon cancer cells in vivo. Oncogene 26:4049–58
  • Scott KA, Arnott CH, Robinson SC, et al. (2004). TNF-alpha regulates epithelial expression of MMP-9 and integrin alphavbeta6 during tumour promotion. A role for TNF-alpha in keratinocyte migration? Oncogene 23:6954–66
  • Sela-Passwell N, Kikkeri R, Dym O, et al. (2012). Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential. Nat Med 18:143–7
  • Sela-Passwell N, Rosenblum G, Shoham T, Sagi I. (2010). Structural and functional bases for allosteric control of MMP activities: can it pave the path for selective inhibition? Biochim Biophys Acta 1803:29–38
  • Senior RM, Griffin GL, Fliszar CJ, et al. (1991). Human 92- and 72-kilodalton type IV collagenases are elastases. J Biol Chem 266:7870–5
  • Sharshar T, Durand MC, Lefaucheur JP, et al. (2002). MMP-9 correlates with electrophysiologic abnormalities in Guillain-Barre syndrome. Neurology 59:1649–51
  • Sheen P, O'Kane CM, Chaudhary K, et al. (2009). High MMP-9 activity characterises pleural tuberculosis correlating with granuloma formation. Eur Respir J 33:134–41
  • Sheu BC, Lien HC, Ho HN, et al. (2003). Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. Cancer Res 63:6537–42
  • Shieh YS, Lai CY, Kao YR, et al. (2005). Expression of axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia 7:1058–64
  • Shimanovich I, Mihai S, Oostingh GJ, et al. (2004). Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid. J Pathol 204:519–27
  • Shin MH, Moon YJ, Seo JE, et al. (2008). Reactive oxygen species produced by NADPH oxidase, xanthine oxidase, and mitochondrial electron transport system mediate heat shock-induced MMP-1 and MMP-9 expression. Free Radic Biol Med 44:635–45
  • Shipley JM, Doyle GA, Fliszar CJ, et al. (1996). The structural basis for the elastolytic activity of the 92-kDa and 72-kDa gelatinases. Role of the fibronectin type II-like repeats. J Biol Chem 271:4335–41
  • Shishodia S, Potdar P, Gairola CG, Aggarwal BB. (2003). Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-kappaB activation through inhibition of IkappaBalpha kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1. Carcinogenesis 24:1269–79
  • Shoji A, Kabeya M, Sugawara M. (2011). Real-time monitoring of matrix metalloproteinase-9 collagenolytic activity with a surface plasmon resonance biosensor. Anal Biochem 419:53–60
  • Sier CF, Casetta G, Verheijen JH, et al. (2000). Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers. Clin Cancer Res 6:2333–40
  • Siskova Z, Yong VW, Nomden A, et al. (2009). Fibronectin attenuates process outgrowth in oligodendrocytes by mislocalizing MMP-9 activity. Mol Cell Neurosci 42:234–42
  • Sivak JM, Fini ME. (2002). MMPs in the eye: emerging roles for matrix metalloproteinases in ocular physiology. Prog Retin Eye Res 21:1–14
  • Sorbi D, Fadly M, Hicks R, et al. (1993). Captopril inhibits the 72 kDa and 92 kDa matrix metalloproteinases. Kidney Int 44:1266–72
  • Sorsa T, Golub LM. (2005). Is the excessive inhibition of matrix metalloproteinases (MMPs) by potent synthetic MMP inhibitors (MMPIs) desirable in periodontitis and other inflammatory diseases? That is: ‘Leaky' MMPIs vs excessively efficient drugs. Oral Dis 11:408–9
  • Speidl WS, Kastl SP, Hutter R, et al. (2011). The complement component C5a is present in human coronary lesions in vivo and induces the expression of MMP-1 and MMP-9 in human macrophages in vitro. FASEB J 25:35–44
  • Speidl WS, Toller WG, Kaun C, et al. (2004). Catecholamines potentiate LPS-induced expression of MMP-1 and MMP-9 in human monocytes and in the human monocytic cell line U937: possible implications for peri-operative plaque instability. FASEB J 18:603–5
  • Spessotto P, Rossi FM, Degan M, et al. (2002). Hyaluronan-CD44 interaction hampers migration of osteoclast-like cells by down-regulating MMP-9. J Cell Biol 158:1133–44
  • Springman EB, Angleton EL, Birkedal-Hansen H, Van Wart HE. (1990). Multiple modes of activation of latent human fibroblast collagenase: evidence for the role of a Cys73 active-site zinc complex in latency and a “cysteine switch” mechanism for activation. Proc Natl Acad Sci USA 87:364–8
  • Starckx S, Van den Steen PE, Verbeek R, et al. (2003). A novel rationale for inhibition of gelatinase B in multiple sclerosis: MMP-9 destroys alpha B-crystallin and generates a promiscuous T cell epitope. J Neuroimmunol 141:47–57
  • Steenport M, Khan KM, Du B, et al. (2009). Matrix metalloproteinase (MMP)-1 and MMP-3 induce macrophage MMP-9: evidence for the role of TNF-alpha and cyclooxygenase-2. J Immunol 183:8119–27
  • Stefanidakis M, Bjorklund M, Ihanus E, et al. (2003). Identification of a negatively charged peptide motif within the catalytic domain of progelatinases that mediates binding to leukocyte beta 2 integrins. J Biol Chem 278:34674–84
  • Steffensen B, Wallon UM, Overall CM. (1995). Extracellular matrix binding properties of recombinant fibronectin type II-like modules of human 72-kDa gelatinase/type IV collagenase. High affinity binding to native type I collagen but not native type IV collagen. J Biol Chem 270:11555–66
  • Stitt AW. (2010). AGEs and diabetic retinopathy. Invest Ophthalmol Vis Sci 51:4867–74
  • Stone SR, Nick H, Hofsteenge J, Monard D. (1987). Glial-derived neurite-promoting factor is a slow-binding inhibitor of trypsin, thrombin, and urokinase. Arch Biochem Biophys 252:237–44
  • Straat K, Gredmark-Russ S, Eriksson P, et al. (2009). Infection with human cytomegalovirus alters the MMP-9/TIMP-1 balance in human macrophages. J Virol 83:830–5
  • Stuelten CH, DaCosta BS, Arany PR, et al. (2005). Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-alpha and TGF-beta. J Cell Sci 118:2143–53
  • Sugimoto K, Yasujima M, Yagihashi S. (2008). Role of advanced glycation end products in diabetic neuropathy. Curr Pharm Des 14:953–61
  • Sultan S, Gosling M, Nagase H, Powell JT. (2004). Shear stress-induced shedding of soluble intercellular adhesion molecule-1 from saphenous vein endothelium. FEBS Lett 564:161–5
  • Sun W, Fujimoto J, Tamaya T. (2004). Coexpression of Gas6/Axl in human ovarian cancers. Oncology 66:450–7
  • Tai KY, Shieh YS, Lee CS, et al. (2008). Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-kappaB and Brg-1. Oncogene 27:4044–55
  • Tai SH, Chen HY, Lee EJ, et al. (2010). Melatonin inhibits postischemic matrix metalloproteinase-9 (MMP-9) activation via dual modulation of plasminogen/plasmin system and endogenous MMP inhibitor in mice subjected to transient focal cerebral ischemia. J Pineal Res 49:332–41
  • Takagi S, Simizu S, Osada H. (2009). RECK negatively regulates matrix metalloproteinase-9 transcription. Cancer Res 69:1502–8
  • Takahashi C, Sheng Z, Horan TP, et al. (1998). Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc Natl Acad Sci USA 95:13221–6
  • Takeuchi T, Hisanaga M, Nagao M, et al. (2004). The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer. Clin Cancer Res 10:5572–9
  • Tang SC, Leung JC, Lai KN. (2011). Diabetic tubulopathy: an emerging entity. Contrib Nephrol 170:124–34
  • Tang Y, Kesavan P, Nakada MT, Yan L. (2004). Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN. Mol Cancer Res 2:73–80
  • Taraboletti G, D'Ascenzo S, Borsotti P, et al. (2002). Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells. Am J Pathol 160:673–80
  • Tonti GA, Mannello F, Cacci E, Biagioni S. (2009). Neural stem cells at the crossroads: MMPs may tell the way. Int J Dev Biol 53:1–17
  • Toth M, Chvyrkova I, Bernardo MM, et al. (2003). Pro-MMP-9 activation by the MT1-MMP/MMP-2 axis and MMP-3: role of TIMP-2 and plasma membranes. Biochem Biophys Res Commun 308:386–95
  • Triebel S, Blaser J, Reinke H, Tschesche H. (1992). A 25 kDa alpha 2-microglobulin-related protein is a component of the 125 kDa form of human gelatinase. FEBS Lett 314:386–8
  • Tsai HT, Su PH, Lee TH, et al. (2011). Significant elevation and correlation of plasma neutrophil gelatinase associated lipocalin and its complex with matrix metalloproteinase-9 in patients with pelvic inflammatory disease. Clin Chim Acta 412:1252–6
  • Tsui W, Pierre K, Massel D. (2005). Patient reperfusion preferences in acute myocardial infarction: mortality versus stroke, benefits versus costs, high technology versus drugs. Can J Cardiol 21:423–31
  • Turner NA, Aley PK, Hall KT, et al. (2007). Simvastatin inhibits TNFalpha-induced invasion of human cardiac myofibroblasts via both MMP-9-dependent and -independent mechanisms. J Mol Cell Cardiol 43:168–76
  • Turner NA, O'Regan DJ, Ball SG, Porter KE. (2005). Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels. FASEB J 19:804–6
  • Turpeenniemi-Hujanen T. (2005). Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 87:287–97
  • Ugarte-Berzal E, Bailon E, Amigo-Jimenez I, et al. (2012). A 17-residue sequence from the matrix metalloproteinase-9 (MMP-9) hemopexin domain binds alpha4beta1 integrin and inhibits MMP-9-induced functions in chronic lymphocytic leukemia B cells. J Biol Chem 287:27601–13
  • Vaisar T, Kassim SY, Gomez IG, et al. (2009). MMP-9 sheds the beta2 integrin subunit (CD18) from macrophages. Mol Cell Proteomics 8:1044–60
  • Van den Steen P, Rudd PM, Dwek RA, Opdenakker G. (1998). Concepts and principles of O-linked glycosylation. Crit Rev Biochem Mol Biol 33:151–208
  • Van den Steen PE, Dubois B, Nelissen I, et al. (2002a). Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 37:375–436
  • Van den Steen PE, Opdenakker G, Wormald MR, et al. (2001). Matrix remodelling enzymes, the protease cascade and glycosylation. Biochim Biophys Acta 1528:61–73
  • Van den Steen PE, Proost P, Brand DD, et al. (2004). Generation of glycosylated remnant epitopes from human collagen type II by gelatinase B. Biochemistry 43:10809–16
  • Van den Steen PE, Proost P, Grillet B, et al. (2002b). Cleavage of denatured natural collagen type II by neutrophil gelatinase B reveals enzyme specificity, post-translational modifications in the substrate, and the formation of remnant epitopes in rheumatoid arthritis. FASEB J 16:379–89
  • Van den Steen PE, Proost P, Wuyts A, et al. (2000). Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 96:2673–81
  • Van den Steen PE, Van Aelst I, Hvidberg V, et al. (2006). The hemopexin and O-glycosylated domains tune gelatinase B/MMP-9 bioavailability via inhibition and binding to cargo receptors. J Biol Chem 281:18626–37
  • van der Jagt MF, Sweep FC, Waas ET, et al. (2006). Correlation of reversion-inducing cysteine-rich protein with kazal motifs (RECK) and extracellular matrix metalloproteinase inducer (EMMPRIN), with MMP-2, MMP-9, and survival in colorectal cancer. Cancer Lett 237:289–97
  • van Ginkel PR, Gee RL, Shearer RL, et al. (2004). Expression of the receptor tyrosine kinase Axl promotes ocular melanoma cell survival. Cancer Res 64:128–34
  • Van Valckenborgh E, Mincher D, Di Salvo A, et al. (2005). Targeting an MMP-9-activated prodrug to multiple myeloma-diseased bone marrow: a proof of principle in the 5T33MM mouse model. Leukemia 19:1628–33
  • Vande Broek I, Asosingh K, Allegaert V, et al. (2004). Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor. Leukemia 18:976–82
  • Vandooren J, Geurts N, Martens E, et al. (2011). Gelatin degradation assay reveals MMP-9 inhibitors and function of O-glycosylated domain. World J Biol Chem 2:14–24
  • Vandooren J, Geurts N, Martens E, et al. (2013). Zymography methods for visualizing hydrolytic enzymes. Nat Methods. DOI:10.1038/nmeth.2371
  • Vanlaere I, Libert C. (2009). Matrix metalloproteinases as drug targets in infections caused by gram-negative bacteria and in septic shock. Clin Microbiol Rev 22:224–39
  • Velada I, Capela-Silva F, Reis F, et al. (2011). Expression of genes encoding extracellular matrix macromolecules and metalloproteinases in avian tibial dyschondroplasia. J Comp Pathol 145:174–86
  • Velders GA, van Os R, Hagoort H, et al. (2004). Reduced stem cell mobilization in mice receiving antibiotic modulation of the intestinal flora: involvement of endotoxins as cofactors in mobilization. Blood 103:340–6
  • Verleden SE, Vandooren J, Vos R, et al. (2011). Azithromycin decreases MMP-9 expression in the airways of lung transplant recipients. Transpl Immunol 25:159–62
  • Vermaelen KY, Cataldo D, Tournoy K, et al. (2003). Matrix metalloproteinase-9-mediated dendritic cell recruitment into the airways is a critical step in a mouse model of asthma. J Immunol 171:1016–22
  • Vierstraete E, Verleyen P, Baggerman G, et al. (2004). A proteomic approach for the analysis of instantly released wound and immune proteins in Drosophila melanogaster hemolymph. Proc Natl Acad Sci USA 101:470–5
  • Villa JP, Bertenshaw GP, Bylander JE, Bond JS. (2003). Meprin proteolytic complexes at the cell surface and in extracellular spaces. Biochem Soc Symp 70:53–63
  • Volkman HE, Pozos TC, Zheng J, et al. (2010). Tuberculous granuloma induction via interaction of a bacterial secreted protein with host epithelium. Science 327:466–9
  • Volpert OV, Ward WF, Lingen MW, et al. (1996). Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 98:671–9
  • von Ballmoos C, Cook GM, Dimroth P. (2008). Unique rotary ATP synthase and its biological diversity. Annu Rev Biophys 37:43–64
  • Vu TH, Shipley JM, Bergers G, et al. (1998). MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93:411–22
  • Wang BQ, Zhang CM, Gao W, et al. (2011). Cancer-derived matrix metalloproteinase-9 contributes to tumor tolerance. J Cancer Res Clin Oncol 137:1525–33
  • Wang FM, Liu HQ, Liu SR, et al. (2005). SHP-2 promoting migration and metastasis of MCF-7 with loss of E-cadherin, dephosphorylation of FAK and secretion of MMP-9 induced by IL-1beta in vivo and in vitro. Breast Cancer Res Treat 89:5–14
  • Wang HH, Hsieh HL, Yang CM. (2010). Calmodulin kinase II-dependent transactivation of PDGF receptors mediates astrocytic MMP-9 expression and cell motility induced by lipoteichoic acid. J Neuroinflammation 7:84
  • Wang J, An H, Mayo MW, et al. (2007). LZAP, a putative tumor suppressor, selectively inhibits NF-kappaB. Cancer Cell 12:239–51
  • Wang X, Yu YY, Lieu S, et al. (2012). MMP9 regulates the cellular response to inflammation after skeletal injury. Bone 52:111–19
  • Wang XB, Bozdagi O, Nikitczuk JS, et al. (2008). Extracellular proteolysis by matrix metalloproteinase-9 drives dendritic spine enlargement and long-term potentiation coordinately. Proc Natl Acad Sci USA 105:19520–5
  • Wang XJ. (2001). Role of TGFbeta signaling in skin carcinogenesis. Microsc Res Tech 52:420–9
  • Welm B, Mott J, Werb Z. (2002). Developmental biology: vasculogenesis is a wreck without RECK. Curr Biol 12:209–11
  • Werb Z, Mainardi CL, Vater CA, Harris ED Jr. (1977). Endogenous activiation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator. N Engl J Med 296:1017–23
  • Whatling C, McPheat W, Hurt-Camejo E. (2004). Matrix management: assigning different roles for MMP-2 and MMP-9 in vascular remodeling. Arterioscler Thromb Vasc Biol 24:10–11
  • Whiteside EJ, Jackson MM, Herington AC, et al. (2001). Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-3 are key regulators of extracellular matrix degradation by mouse embryos. Biol Reprod 64:1331–7
  • Wilhelm SM, Collier IE, Marmer BL, et al. (1989). SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem 264:17213–21
  • Winberg JO, Berg E, Kolset SO, Uhlin-Hansen L. (2003). Calcium-induced activation and truncation of promatrix metalloproteinase-9 linked to the core protein of chondroitin sulfate proteoglycans. Eur J Biochem 270:3996–4007
  • Winberg JO, Kolset SO, Berg E, Uhlin-Hansen L. (2000). Macrophages secrete matrix metalloproteinase 9 covalently linked to the core protein of chondroitin sulphate proteoglycans. J Mol Biol 304:669–80
  • Wong HP, Ho JW, Koo MW, et al. (2011). Effects of adrenaline in human colon adenocarcinoma HT-29 cells. Life Sci 88:1108–12
  • Wu CW, Li AF, Chi CW, et al. (2002). Clinical significance of AXL kinase family in gastric cancer. Anticancer Res 22:1071–8
  • Wu CY, Hsieh HL, Jou MJ, Yang CM. (2004). Involvement of p42/p44 MAPK, p38 MAPK, JNK and nuclear factor-kappa B in interleukin-1beta-induced matrix metalloproteinase-9 expression in rat brain astrocytes. J Neurochem 90:1477–88
  • Wu CY, Hsieh HL, Sun CC, Yang CM. (2009). IL-1beta induces MMP-9 expression via a Ca2+-dependent CaMKII/JNK/c-JUN cascade in rat brain astrocytes. Glia 57:1775–89
  • Wu L, Derynck R. (2009). Essential role of TGF-beta signaling in glucose-induced cell hypertrophy. Dev Cell 17:35–48
  • Wu X, Brewer G. (2012). The regulation of mRNA stability in mammalian cells: 2.0. Gene 500:10–21
  • Xu D, McKee CM, Cao Y, et al. (2010). Matrix metalloproteinase-9 regulates tumor cell invasion through cleavage of protease nexin-1. Cancer Res 70:6988–98
  • Xu D, Suenaga N, Edelmann MJ, et al. (2008). Novel MMP-9 substrates in cancer cells revealed by a label-free quantitative proteomics approach. Mol Cell Proteomics 7:2215–28
  • Xu P, Alfaidy N, Challis JR. (2002). Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in human placenta and fetal membranes in relation to preterm and term labor. J Clin Endocrinol Metab 87:1353–61
  • Xu S, Venge P. (2000). Lipocalins as biochemical markers of disease. Biochim Biophys Acta 1482:298–307
  • Xu X, Chen Z, Wang Y, et al. (2005). Functional basis for the overlap in ligand interactions and substrate specificities of matrix metalloproteinases-9 and -2. Biochem J 392:127–34
  • Xue M, Jackson CJ. (2008). Autocrine actions of matrix metalloproteinase (MMP)-2 counter the effects of MMP-9 to promote survival and prevent terminal differentiation of cultured human keratinocytes. J Invest Dermatol 128:2676–85
  • Xue M, Mikliaeva EI, Casha S, et al. (2010). Improving outcomes of neuroprotection by minocycline: guides from cell culture and intracerebral hemorrhage in mice. Am J Pathol 176:1193–202
  • Yagi K, Kitazato KT, Uno M, et al. (2009). Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator. Stroke 40:626–31
  • Yakubenko VP, Lobb RR, Plow EF, Ugarova TP. (2000). Differential induction of gelatinase B (MMP-9) and gelatinase A (MMP-2) in T lymphocytes upon alpha(4)beta(1)-mediated adhesion to VCAM-1 and the CS-1 peptide of fibronectin. Exp Cell Res 260:73–84
  • Yamamoto D, Takai S, Jin D, et al. (2007). Molecular mechanism of imidapril for cardiovascular protection via inhibition of MMP-9. J Mol Cell Cardiol 43:670–6
  • Yamamoto H, Vinitketkumnuen A, Adachi Y, et al. (2004). Association of matrilysin-2 (MMP-26) expression with tumor progression and activation of MMP-9 in esophageal squamous cell carcinoma. Carcinogenesis 25:2353–60
  • Yan C, Wang H, Boyd DD. (2001a). KiSS-1 represses 92-kDa type IV collagenase expression by down-regulating NF-kappa B binding to the promoter as a consequence of Ikappa Balpha -induced block of p65/p50 nuclear translocation. J Biol Chem 276:1164–72
  • Yan L, Borregaard N, Kjeldsen L, Moses MA. (2001b). The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 276:37258–65
  • Yan W, Zhang W, Sun L, et al. (2011). Identification of MMP-9 specific microRNA expression profile as potential targets of anti-invasion therapy in glioblastoma multiforme. Brain Res 1411:108–15
  • Yang C, Zhu P, Yan L, et al. (2009). Dynamic changes in matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 levels during wound healing in diabetic rats. J Am Podiatr Med Assoc 99:489–96
  • Yang EV, Sood AK, Chen M, et al. (2006). Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res 66:10357–64
  • Yang JM, Xu Z, Wu H, et al. (2003). Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells. Mol Cancer Res 1:420–7
  • Yang X, Zhang P, Ma Q, et al. (2012). EMMPRIN contributes to the in vitro invasion of human salivary adenoid cystic carcinoma cells. Oncol Rep 27:1123–7
  • Yasmin, McEniery CM, Wallace S, et al. (2005). Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 25:372--8
  • Yasojima K, Schwab C, McGeer EG, McGeer PL. (2001). Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 158:1039–51
  • Yong VW. (2005). Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci 6:931–44
  • Yong VW, Krekoski CA, Forsyth PA, et al. (1998). Matrix metalloproteinases and diseases of the CNS. Trends Neurosci 21:75–80
  • Yong VW, Wells J, Giuliani F, et al. (2004). The promise of minocycline in neurology. Lancet Neurol 3:744–51
  • Yu Q, Stamenkovic I. (2000). Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14:163–76
  • Yu W, Liu J, Xiong X, et al. (2009). Expression of MMP9 and CD147 in invasive squamous cell carcinoma of the uterine cervix and their implication. Pathol Res Pract 205:709–15
  • Yu X, Huang Y, Collin-Osdoby P, Osdoby P. (2003). Stromal cell-derived factor-1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration. J Bone Miner Res 18:1404–18
  • Zabad RK, Metz LM, Todoruk TR, et al. (2007). The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study. Mult Scler 13:517–26
  • Zhang C, Chakravarty D, Sakabe I, et al. (2006). Role of SCC-S2 in experimental metastasis and modulation of VEGFR-2, MMP-1, and MMP-9 expression. Mol Ther 13:947–55
  • Zhang F, Banker G, Liu X, et al. (2011). The novel function of advanced glycation end products in regulation of MMP-9 production. J Surg Res 171:871–6
  • Zhang H, Qi M, Li S, et al. (2012). microRNA-9 targets matrix metalloproteinase 14 to inhibit invasion, metastasis, and angiogenesis of neuroblastoma cells. Mol Cancer Ther 11:1454–66
  • Zhao YG, Xiao AZ, Newcomer RG, et al. (2003). Activation of pro-gelatinase B by endometase/matrilysin-2 promotes invasion of human prostate cancer cells. J Biol Chem 278:15056–64
  • Zheng X, Chopp M, Lu Y, et al. (2012). MiR-15b and miR-152 reduce glioma cell invasion and angiogenesis via NRP-2 and MMP-3. Cancer Lett 329:146–54
  • Zhong D, Saito F, Saito Y, et al. (2006). Characterization of the protease activity that cleaves the extracellular domain of beta-dystroglycan. Biochem Biophys Res Commun 345:867–71
  • Zhong WD, Han ZD, He HC, et al. (2008). CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer. Oncology 75:230–6
  • Zhu HJ, Burgess AW. (2001). Regulation of transforming growth factor-beta signaling. Mol Cell Biol Res Commun 4:321–30

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.